Search Results
Oct 15, 2025, 09:00 ET GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Hypersensitivity: In case of hypersensitivity,
More news about: GC Biopharma USA Inc.
Oct 14, 2025, 01:40 ET 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
consistent with prior studies across other autoimmune indications, including systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, and IgA nephropathy. No new safety signals were observed. Most adverse events were mild to moderate in severity. Sjögren's
More news about: RemeGen Co., Ltd
Oct 13, 2025, 09:00 ET GC Biopharma Highlights IVIG Innovation and Investigator-Initiated Research as Science to Solutions Partner at the Fall 2025 CIIC Conference
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Hypersensitivity: In case of hypersensitivity,
More news about: GC Biopharma USA Inc.
Oct 10, 2025, 10:00 ET Pathlock Recognized in the 2025 Gartner® Market Guide for Identity Governance and Administration
and administration (IGA) as "the solution to manage the identity life cycle and govern access across on-premises and cloud environments." Gartner notes "The IGA market worldwide grew 9.2% from 2023 to 2024, with forecast 2024 to 2025 growth of 10.7%, as of 2Q25. The IGA market's growth is increasingly
More news about: Pathlock
Oct 10, 2025, 02:00 ET Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan
standard EU approval for the IgA nephropathy indication in 2025. *FILSPARI® (sparsentan) U.S. Indication: FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary IgA nephropathy who are at
More news about: Renalys Pharma, Inc.
Oct 09, 2025, 10:00 ET Omada Named "Overall ID Management Solution Provider of the Year" in 9th Annual CyberSecurity Breakthrough Awards Program
About OmadaOmada, a global market leader in Identity Governance and Administration (IGA), offers a full-featured, enterprise-grade, cloud native IGA solution that enables organizations to achieve compliance, reduce risk, and maximize efficiency. Founded in 2000, Omada
More news about: Omada
Oct 08, 2025, 08:03 ET Omada Named a Representative Vendor in the 2025 Gartner® Market Guide for Identity Governance and Administration
business drivers, leading to a variety of offered IAM features. This research helps IAM leaders navigate the IGA market and improve decision making." Omada's modern IGA solutions, Omada Identity and Omada Identity Cloud, deliver essential
More news about: Omada
Oct 08, 2025, 08:00 ET SecurEnds Launches Redesigned SMART IGA Platform to Revolutionize Enterprise Identity Governance
SecurEnds today announced the redesigned SMART IGA platform, featuring advanced Access Analysis, Access Templates, and T-Hub powered Provisioning and Deprovisioning. The update delivers smarter analytics,
More news about: SecurEnds
Oct 07, 2025, 09:00 ET Century Health and Balboa Nephrology Partner to Unlock AI-Driven Insights for Clinical Research and Drug Development in Chronic Kidney Diseases
Together, Century Health and Balboa Nephrology will combine clinical expertise with AI to improve care and accelerate treatments in conditions such as IgA nephropathy, lupus nephritis, and C3 glomerulonephritis
More news about: Century Health
Oct 06, 2025, 17:31 ET Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight
IgA Nephropathy Market IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report
More news about: DelveInsight Business Research, LLP
Oct 01, 2025, 07:11 ET RapidIdentity: Leading the Charge in Identity Management for Ohio's Higher Education
that facilitates streamlined and secure access, effectively addressing their evolving Identity and Access Management (IAM) and Identity Governance (IGA) challenges. With RapidIdentity, these institutions now have easy access to a market-leading platform designed specifically to meet the ever-evolving
More news about: Identity Automation, a Jamf company
Sep 29, 2025, 08:00 ET U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
compared to 16% of patients receiving placebo (p<0.001) achieved high levels of skin clearance (IGA score of 0/1). Nearly 40% of pediatric patients receiving TREMFYA® achieved complete clearance (IGA 0) at Week 16 compared to 4% on placebo (p<0.01).6 Approval
More news about: Johnson & Johnson
Sep 29, 2025, 07:00 ET Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations.
you are not sure. You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, and have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.
More news about: Kedrion Biopharma
Sep 26, 2025, 02:30 ET CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
travere.com. About IgA Nephropathy IgA Nephropathy, also called Berger's disease, is a rare progressive kidney disease characterized by the abnormal buildup of immunoglobulin A (IgA), an antibody that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of
More news about: Vifor International AG (CSL Vifor)
Sep 26, 2025, 02:30 ET CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
travere.com. About IgA Nephropathy IgA Nephropathy, also called Berger's disease, is a rare progressive kidney disease characterized by the abnormal buildup of immunoglobulin A (IgA), an antibody that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of
More news about: Vifor International AG (CSL Vifor)
Sep 24, 2025, 09:00 ET ONE IDENTITY NAMES SOFTWARE INDUSTRY LEADER PRAERIT GARG AS CEO
Identity Fabric, a holistic approach to identity and access management (IAM). By unifying IAM tools, including identity governance and administration (IGA), access management (AM), privileged access management (PAM), and Active Directory management (AD Mgmt), it ensures optimal functionality and efficiency.
More news about: One Identity
Sep 22, 2025, 00:15 ET First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
activity and B-cell maturation, providing a synergistic approach to treating autoimmune diseases such as systemic lupus erythematosus, dermatomyositis, IgA nephropathy and Sjögren's syndrome. LBL-047 is further optimized with glycosylation modifications to enhance antibody-dependent cellular cytotoxicity
More news about: Leads Biolabs
Sep 17, 2025, 19:30 ET Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
Primary endpoints included the percent treatment success, defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12, the percent reductions from baseline to week 12 in total lesion count (TLC), and the
More news about: Ascletis Pharma Inc.
Sep 17, 2025, 10:30 ET Agentic ITSM platform Atomicwork announces strategic investment from Okta Ventures
Through this partnership, Atomicwork and Okta will build integrations that embed identity, access intelligence, and IGA into everyday service delivery. For example, when an employee can't access Workday, they simply message Atom (Atomicwork's Universal AI Agent)
More news about: Atomicwork Inc
Sep 17, 2025, 08:00 ET Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
the efficacy and safety of icotrokinra compared with placebo and deucravacitinib in participants with moderate-to-severe plaque PsO with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.b. Drs. Soung and Stein Gold are
More news about: Johnson & Johnson
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
expected to commence in January 2026. BW-40202 is also being evaluated in a Phase I study as a potential treatment for IgA Nephropathy (IgAN). The Phase I/IIa IND approval was obtained from the NMPA in China in June
More news about: Argo Biopharmaceutical Co., Ltd.
Sep 14, 2025, 19:45 ET 耐賦康®7項最新真實世界數據將亮相第18屆IgA腎病國際研討會
李貴森，四川省醫學科學院•四川省人民醫院 04 編號：P-63英文標題：First real-world evidence of Nefecon efficacy in pediatric patients with IgA nephropathy or IgA vasculitis nephritis中文標題：首個耐賦康®對兒童IgA腎病或IgA血管炎腎炎的療效的真實世界證據內容概述：旨在評估耐賦康®對兒童IgA腎病或IgA血
More news about: 雲頂新耀
Sep 11, 2025, 08:03 ET Omada simplifies and accelerates IGA deployment while lowering total cost of ownership
Omada Identity Cloud, the company's IGA-as-a-service platform, and on-premises or cloud-hosted target systems. This can be done without requiring changes to firewall configurations, offering agility and Zero Trust alignment, ideal for modern, distributed IGA deployments.
More news about: Omada